I've made no secret of my abiding respect for Stryker ( SYK ) and its ability to leverage M&A and disruptive internal R&D to target and deliver on above-average growth opportunities in med-tech. In the roughly seven years Kevin Lobo has been the CEO, the company has spent $14 billion…